All Articles

As pharma giants dominate the obesity space with GLP-1 drugs, Corbus Pharmaceuticals is betting on a different mechanism. Will its upcoming data rewrite the rules?

As BRICS marks its 20th year in New Delhi, the expanded bloc aims to lead the Global South. But can it overcome internal rivalries and global pressures?

Quebec-based Devonian Health Group plans a NYSE American debut, seeking U.S. capital to advance its promising pipeline of autoimmune disease treatments.

At NYFW, a wig brand didn't just show off hair; it revealed a calculated strategy to redefine an industry and solidify its leadership.

With the hire of a legal expert, Menlo Business Brokerage is betting that integrated expertise is the key to navigating today's complex M&A landscape.

With a new FDA nod for its rare disease drug Joenja, Pharming offers hope to young children, signaling a strategic shift in how we treat complex genetic disorders.

As AdaptHealth hits the investor circuit, it faces tough questions on profitability, strategy shifts, and recent setbacks. Can leadership reassure the market?

As users flee the noise of public social media, platforms like CallMeChat promise quiet, meaningful connection. But a closer look reveals a complex reality.

The race to build AI's future runs on 18-wheelers carrying colossal cargo. But as data centers boom, a hidden crisis in heavy-haul logistics emerges.

As Vancouver's iconic FIFA dome is dismantled, a savvy strategy emerges. It's more than upcycling; it's a masterclass in monetizing goodwill and ESG.

Mary Alice Stephenson's award nomination isn't just a nod to charity. It's a signal that the beauty industry now views systemic, sustainable impact as innovation.

A Michigan biotech just patented a way to turn yeast into tiny drug factories inside you. It’s a blueprint for a future without injections or cold chains.

A new partnership aims to solve Asia's AI power crisis by pairing computing with renewables. Can this green blueprint redefine tech growth in the region?

The firm's successful offering, featuring a striking 17% yield on Class A shares, signals strong investor appetite but also highlights the complex risks of split corps.

As AI floods creative industries, Proudly Human appoints a musician to lead its North American charge for a 'certified human' label. Is this the future of art?

With FDA approval for its RefluxStop® device, Implantica challenges the GERD treatment status quo, promising better outcomes without debilitating side effects.

ALLSWIFIT's new ActiveRise+ shoe promises elite speed and stability for everyday runners. But can a newcomer deliver on bold claims in a crowded market?

Glucotrack secures $11.5M to fund a breakthrough diabetes monitor, but a look beneath the surface reveals a high-stakes gamble on AI and shareholder value.

A new study reveals an mRNA flu vaccine sustains immune responses for months, a breakthrough that could lead to multi-season protection and end the annual flu shot.

PolarX's stunning copper find in Alaska, with grades dwarfing global averages, is more than a lucky strike—it's a calculated play backed by a mining giant.